Background: Rapid antigen assays have been attractive for decentralized, point of care diagnostics because of their low cost, robustness, and ease of use. The development of a diagnostic assay for a newly emerging infectious disease needs to take into account the progression of a disease, whether there is human to human transmission, and patient biomarker levels with time, and these all impact the choice of antigen targets and affinity agents.
Scope of review: The factors involved in the biophysical design of rapid antigen immunoassays are discussed, focusing on antigen selection and designing for cross-reactivity. State of the art in the biophysical characterization of protein-ligand or antigen-antibody interactions, the different types of affinity agents used in immunoassays, and biochemical conjugation strategies are described.
Major conclusions: Antigen choice is a critical factor in immunoassay diagnostic development, and should account for the properties of the virion, virus, and disease progression. Biophysical and biochemical aspects of immunoassays are critical for performance.
General significance: This review can serve as an instructive guide to aid in diagnostic development for future emerging diseases.
Keywords: Infectious diseases; Lateral flow immunoassay; Nanoparticle-antibody conjugates; Paperfluidic; Protein-ligand affinity; Rapid diagnostic; Viral biomarkers.
Copyright © 2022 Elsevier B.V. All rights reserved.